iifl-logo

Twilight Litaka Pharma Ltd Share Price

4.25
(0.00%)
Dec 10, 2014|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Twilight Litaka Pharma Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

4.45

Prev. Close

4.25

Turnover(Lac.)

0.37

Day's High

4.45

Day's Low

4.15

52 Week's High

0

52 Week's Low

0

Book Value

-59.61

Face Value

5

Mkt Cap (₹ Cr.)

10.53

P/E

0

EPS

0

Divi. Yield

0

Twilight Litaka Pharma Ltd Corporate Action

No Record Found

Twilight Litaka Pharma Ltd NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Twilight Litaka Pharma Ltd SHAREHOLDING SNAPSHOT

02 Apr, 2025|07:01 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 1.27%

Foreign: 0.00%

Indian: 1.27%

Non-Promoter- 6.48%

Institutions: 6.47%

Non-Institutions: 92.24%

Custodian: 0.00%

Share Price

Twilight Litaka Pharma Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Jun-2014Jun-2013Mar-2012Mar-2011

Equity Capital

12.39

12.39

12.39

18.17

Preference Capital

0

0

0

0

Reserves

-133.3

6.29

169.03

136.89

Net Worth

-120.91

18.68

181.42

155.06

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Jun-2014Jun-2013Mar-2012Mar-2011

Revenue

31.5

337.49

730.18

657.34

yoy growth (%)

-90.66

-53.77

11.08

Raw materials

-19.89

-296.54

-561.8

-505.86

As % of sales

63.15

87.86

76.94

76.95

Employee costs

-4.81

-10.12

-19.98

-17.67

View Profit & Loss
Y/e 31 Mar( In .Cr)Jun-2014Jun-2013Mar-2012Mar-2011

Profit before tax

-14.12

-48.32

19.47

63.38

Depreciation

-4.97

-6.4

-5.1

-3.64

Tax paid

0

0

-0.92

-13.93

Working capital

-120.21

-141.58

55.95

Other operating items

View Cash Flow
Y/e 31 MarJun-2014Jun-2013Mar-2012Mar-2011

Growth matrix (%)

Revenue growth

-90.66

-53.77

11.08

Op profit growth

-78.72

-160

-30.14

EBIT growth

-71.02

-173.41

-33.96

Net profit growth

-13.13

-4,712.22

-92.88

View Ratios
Particulars (Rupees in Crores.)Jun-2014Mar-2012Mar-2011

Gross Sales

31.5

732.55

670.83

Excise Duty

0

0

0

Net Sales

31.5

732.55

670.83

Other Operating Income

0

0

0

Other Income

0

1.11

3.25

Twilight Litaka Pharma Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceutical Industries Ltd

SUNPHARMA

1,698.35

129.244,07,155.151,181.050.85,985.3398.33

Divis Laboratories Ltd

DIVISLAB

5,549.7

71.051,47,295.245940.542,297513.62

Cipla Ltd

CIPLA

1,444.25

25.071,16,664.331,438.150.94,134.87360.73

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,183.9

59.031,07,673.274850.882,330222.38

Mankind Pharma Ltd

MANKIND

2,458.1

52.421,01,358.17416.3802,396.57334.17

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Twilight Litaka Pharma Ltd

Management

Register Office

Registrar Office

Chairman

R C Bora

Managing Director

Gopal Ramourti

Executive Director & CFO

N R Bora

Director

A S Chandvankar

Director

M S Raghavan Ayyangar

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Incorporated as a private limited company in Jan.74, Li Taka Pharmaceuticals was converted into a public limited company in Dec.85. Li Taka Laboratories Pvt Ltd was amalgamated with the company in 1986.The company is engaged in the manufacture of various drugs and pharmaceuticals formulations. It also manufactures formulations on loan licence basis as well as on principal to principal basis for various multinational companies like Hindustan Ciba Geigy, Pfizer and Burroughs Wellcome. Its manufacturing facility is located at Pimpri, Pune.The company came out with a rights issue in Apr.92 to meet the long-term working capital requirements of the company and to part-finance its normal capital expenditure including modernisation.In Jun.95, Pegasus Laboratories was amalgamated with the company. The company exported goods worth Rs 1.14 cr in 1996-97.During 1997-98, the company has purchased Marketing division of Borachem Industries Ltd., With this arrangement the companys product will be represented in almost all the major parts of the country. There is a rise of 88.53% in the sales over the previous year. To give more emphasis on own operations the marketing alliance with Smithkline Beecham Pharmaceuticlas (I) Ltd. has been terminated.The company is planning to introduce new products for domestic and internation market.
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.